Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Mechanistic understanding of the phase behavior of supersaturated solutions of poorly water-soluble drugs.

Tres F, Posada MM, Hall SD, Mohutsky MA, Taylor LS.

Int J Pharm. 2018 May 30;543(1-2):29-37. doi: 10.1016/j.ijpharm.2018.03.038. Epub 2018 Mar 20.

PMID:
29572154
2.

Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance.

Coutant DE, Hall SD.

J Clin Pharmacol. 2018 Jul;58(7):849-863. doi: 10.1002/jcph.1093. Epub 2018 Mar 5. Review.

PMID:
29505093
3.

Transient Alpha and Beta Synchrony Underlies Preparatory Recruitment of Directional Motor Networks.

Rhodes E, Gaetz WC, Marsden J, Hall SD.

J Cogn Neurosci. 2018 Jun;30(6):867-875. doi: 10.1162/jocn_a_01250. Epub 2018 Feb 28.

PMID:
29488848
4.

Proof of Concept Coded Aperture Miniature Mass Spectrometer Using a Cycloidal Sector Mass Analyzer, a Carbon Nanotube (CNT) Field Emission Electron Ionization Source, and an Array Detector.

Amsden JJ, Herr PJ, Landry DMW, Kim W, Vyas R, Parker CB, Kirley MP, Keil AD, Gilchrist KH, Radauscher EJ, Hall SD, Carlson JB, Baldasaro N, Stokes D, Di Dona ST, Russell ZE, Grego S, Edwards SJ, Sperline RP, Denton MB, Stoner BR, Gehm ME, Glass JT.

J Am Soc Mass Spectrom. 2018 Feb;29(2):360-372. doi: 10.1007/s13361-017-1820-y. Epub 2017 Oct 19.

PMID:
29052038
5.

Monitoring the Phase Behavior of Supersaturated Solutions of Poorly Water-Soluble Drugs Using Fluorescence Techniques.

Tres F, Hall SD, Mohutsky MA, Taylor LS.

J Pharm Sci. 2018 Jan;107(1):94-102. doi: 10.1016/j.xphs.2017.10.002. Epub 2017 Oct 12.

PMID:
29031978
6.

Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.

Posada MM, Cannady EA, Payne CD, Zhang X, Bacon JA, Pak YA, Higgins JW, Shahri N, Hall SD, Hillgren KM.

Clin Transl Sci. 2017 Nov;10(6):509-519. doi: 10.1111/cts.12486. Epub 2017 Jul 27.

PMID:
28749581
7.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.

Rougée LRA, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2017 Sep;45(9):1008-1018. doi: 10.1124/dmd.117.076331. Epub 2017 Jul 5.

PMID:
28679672
8.

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: II. Validity Studies of the Pause Marker.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL.

J Speech Lang Hear Res. 2017 Apr 14;60(4):S1118-S1134. doi: 10.1044/2016_JSLHR-S-15-0297.

9.

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: I. Development and Description of the Pause Marker.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL.

J Speech Lang Hear Res. 2017 Apr 14;60(4):S1096-S1117. doi: 10.1044/2016_JSLHR-S-15-0296. Review.

10.

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: III. Theoretical Coherence of the Pause Marker with Speech Processing Deficits in Childhood Apraxia of Speech.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL.

J Speech Lang Hear Res. 2017 Apr 14;60(4):S1135-S1152. doi: 10.1044/2016_JSLHR-S-15-0298.

11.

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: Introduction.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL.

J Speech Lang Hear Res. 2017 Apr 14;60(4):S1094-S1095. doi: 10.1044/2016_JSLHR-S-16-0148.

12.

A Diagnostic Marker to Discriminate Childhood Apraxia of Speech From Speech Delay: IV. The Pause Marker Index.

Shriberg LD, Strand EA, Fourakis M, Jakielski KJ, Hall SD, Karlsson HB, Mabie HL, McSweeny JL, Tilkens CM, Wilson DL.

J Speech Lang Hear Res. 2017 Apr 14;60(4):S1153-S1169. doi: 10.1044/2016_JSLHR-S-16-0149.

13.

The Risky Side of Creativity: Domain Specific Risk Taking in Creative Individuals.

Tyagi V, Hanoch Y, Hall SD, Runco M, Denham SL.

Front Psychol. 2017 Feb 3;8:145. doi: 10.3389/fpsyg.2017.00145. eCollection 2017.

14.

The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2D6 Substrates.

Rougée LR, Mohutsky MA, Bedwell DW, Ruterbories KJ, Hall SD.

Drug Metab Dispos. 2016 Nov;44(11):1819-1827. Epub 2016 Sep 2.

15.

Overview of the Genetics of Alcohol Use Disorder.

Tawa EA, Hall SD, Lohoff FW.

Alcohol Alcohol. 2016 Sep;51(5):507-14. doi: 10.1093/alcalc/agw046. Epub 2016 Jul 21. Review.

16.

Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism.

Boontanrart M, Hall SD, Spanier JA, Hayes CE, Olson JK.

J Neuroimmunol. 2016 Mar 15;292:126-36. doi: 10.1016/j.jneuroim.2016.01.015. Epub 2016 Jan 27.

PMID:
26943970
17.

The Serum Very-Low-Density Lipoprotein Serves as a Restriction Factor against Hepatitis C Virus Infection.

Tao J, Kang KD, Hall SD, Laube AH, Liu J, Renfrow MB, Novak J, Luo G.

J Virol. 2015 Jul;89(13):6782-91. doi: 10.1128/JVI.00194-15. Epub 2015 Apr 22.

18.

Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.

Steere B, Baker JA, Hall SD, Guo Y.

Drug Metab Dispos. 2015 Jun;43(6):870-83. doi: 10.1124/dmd.114.061523. Epub 2015 Apr 6.

19.

Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.

Coutant DE, Kulanthaivel P, Turner PK, Bell RL, Baldwin J, Wijayawardana SR, Pitou C, Hall SD.

Clin Pharmacol Ther. 2015 Jul;98(1):76-86. doi: 10.1002/cpt.128. Epub 2015 May 19. Review.

PMID:
25808023
20.

Cortical oscillatory dynamics and benzodiazepine-site modulation of tonic inhibition in fast spiking interneurons.

Prokic EJ, Weston C, Yamawaki N, Hall SD, Jones RS, Stanford IM, Ladds G, Woodhall GL.

Neuropharmacology. 2015 Aug;95:192-205. doi: 10.1016/j.neuropharm.2015.03.006. Epub 2015 Mar 20.

21.

Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD.

Clin Pharmacol Ther. 2015 Mar;97(3):247-62. doi: 10.1002/cpt.37. Epub 2015 Jan 9. Review.

PMID:
25670209
22.

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

Small DS, Ke AB, Hall SD, Mantlo N, Rotelli M, Friedrich S.

J Clin Pharmacol. 2015 Jul;55(7):757-67. doi: 10.1002/jcph.472. Epub 2015 Feb 20.

PMID:
25651523
23.

Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling.

Posada MM, Bacon JA, Schneck KB, Tirona RG, Kim RB, Higgins JW, Pak YA, Hall SD, Hillgren KM.

Drug Metab Dispos. 2015 Mar;43(3):325-34. doi: 10.1124/dmd.114.059618. Epub 2014 Dec 12.

24.

Relative contributions of presystemic and systemic peptidases to oral exposure of a novel metabotropic glutamate 2/3 receptor agonist (LY404039) after oral administration of prodrug pomaglumetad methionil (LY2140023).

Annes WF, Long A, Witcher JW, Ayan-Oshodi MA, Knadler MP, Zhang W, Mitchell MI, Cornelissen K, Hall SD.

J Pharm Sci. 2015 Jan;104(1):207-14. doi: 10.1002/jps.24226. Epub 2014 Nov 7.

PMID:
25382826
25.

In vivo real-time 3-D intracardiac echo using PMUT arrays.

Dausch DE, Gilchrist KH, Carlson JB, Hall SD, Castellucci JB, von Ramm OT.

IEEE Trans Ultrason Ferroelectr Freq Control. 2014 Oct;61(10):1754-64. doi: 10.1109/TUFFC.2014.006452.

PMID:
25265183
26.

GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease.

Hall SD, Prokic EJ, McAllister CJ, Ronnqvist KC, Williams AC, Yamawaki N, Witton C, Woodhall GL, Stanford IM.

Neuroscience. 2014 Dec 5;281:68-76. doi: 10.1016/j.neuroscience.2014.09.037. Epub 2014 Sep 28.

27.

Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.

Takahashi K, Raska M, Stuchlova Horynova M, Hall SD, Poulsen K, Kilian M, Hiki Y, Yuzawa Y, Moldoveanu Z, Julian BA, Renfrow MB, Novak J.

PLoS One. 2014 Jun 11;9(2):e99026. doi: 10.1371/journal.pone.0099026. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113577.

28.

Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.

Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD.

Clin Pharmacol Ther. 2014 May;95(5):473-6. doi: 10.1038/clpt.2014.41.

PMID:
24747234
29.

Cerebrospinal fluid monocyte chemoattractant protein-1 in alcoholics: support for a neuroinflammatory model of chronic alcoholism.

Umhau JC, Schwandt M, Solomon MG, Yuan P, Nugent A, Zarate CA, Drevets WC, Hall SD, George DT, Heilig M.

Alcohol Clin Exp Res. 2014 May;38(5):1301-6. doi: 10.1111/acer.12367. Epub 2014 Apr 1.

PMID:
24689518
30.

Irreversible enzyme inhibition kinetics and drug-drug interactions.

Mohutsky M, Hall SD.

Methods Mol Biol. 2014;1113:57-91. doi: 10.1007/978-1-62703-758-7_5. Review.

PMID:
24523109
31.

Spike firing and IPSPs in layer V pyramidal neurons during beta oscillations in rat primary motor cortex (M1) in vitro.

Lacey MG, Gooding-Williams G, Prokic EJ, Yamawaki N, Hall SD, Stanford IM, Woodhall GL.

PLoS One. 2014 Jan 20;9(1):e85109. doi: 10.1371/journal.pone.0085109. eCollection 2014.

32.

Integration of in vitro binding mechanism into the semiphysiologically based pharmacokinetic interaction model between ketoconazole and midazolam.

Quinney SK, Knopp S, Chang C, Hall SD, Li L.

CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2:e75. doi: 10.1038/psp.2013.50.

33.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
34.

Gamma oscillatory amplitude encodes stimulus intensity in primary somatosensory cortex.

Rossiter HE, Worthen SF, Witton C, Hall SD, Furlong PL.

Front Hum Neurosci. 2013 Jul 15;7:362. doi: 10.3389/fnhum.2013.00362. eCollection 2013.

35.

CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.

Xu C, Quinney SK, Guo Y, Hall SD, Li L, Desta Z.

Drug Metab Dispos. 2013 Dec;41(12):2004-11. doi: 10.1124/dmd.113.051755. Epub 2013 Jul 11.

36.

The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.

Topletz AR, Dennison JB, Barbuch RJ, Hadden CE, Hall SD, Renbarger JL.

Drug Metab Dispos. 2013 Sep;41(9):1651-61. doi: 10.1124/dmd.113.051094. Epub 2013 Jun 18.

37.

Live volumetric imaging (LVI) intracardiac ultrasound catheter.

Dausch DE, Castellucci JB, Gilchrist KH, Carlson JB, Hall SD, von Ramm OT.

Cardiovasc Revasc Med. 2013 May-Jun;14(3):157-9. doi: 10.1016/j.carrev.2013.03.008.

PMID:
23773496
38.

Oscillatory beta activity mediates neuroplastic effects of motor cortex stimulation in humans.

McAllister CJ, Rönnqvist KC, Stanford IM, Woodhall GL, Furlong PL, Hall SD.

J Neurosci. 2013 May 1;33(18):7919-27. doi: 10.1523/JNEUROSCI.5624-12.2013.

39.

A multimodal perspective on the composition of cortical oscillations.

Ronnqvist KC, McAllister CJ, Woodhall GL, Stanford IM, Hall SD.

Front Hum Neurosci. 2013 Apr 10;7:132. doi: 10.3389/fnhum.2013.00132. eCollection 2013.

40.

Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole.

Han B, Mao J, Chien JY, Hall SD.

Drug Metab Dispos. 2013 Jul;41(7):1329-38. doi: 10.1124/dmd.112.050732. Epub 2013 Apr 12.

41.

Quantitative structure-activity relationship models of clinical pharmacokinetics: clearance and volume of distribution.

Gombar VK, Hall SD.

J Chem Inf Model. 2013 Apr 22;53(4):948-57. doi: 10.1021/ci400001u. Epub 2013 Mar 15.

PMID:
23451981
42.

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.

Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.

Drug Metab Dispos. 2013 Mar;41(3):541-5. doi: 10.1124/dmd.112.048769. Epub 2012 Dec 10.

43.

Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.

Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R.

Ann Surg. 2013 Aug;258(2):262-9. doi: 10.1097/SLA.0b013e31827a0e82.

PMID:
23222033
44.

Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.

Duke JD, Han X, Wang Z, Subhadarshini A, Karnik SD, Li X, Hall SD, Jin Y, Callaghan JT, Overhage MJ, Flockhart DA, Strother RM, Quinney SK, Li L.

PLoS Comput Biol. 2012;8(8):e1002614. doi: 10.1371/journal.pcbi.1002614. Epub 2012 Aug 9.

45.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ.

J Alzheimers Dis. 2012;32(2):373-85. doi: 10.3233/JAD-2012-120832.

PMID:
22796873
46.

The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

Ayan-Oshodi MA, Willis BA, Annes WF, Lowe SL, Friedrich S, de la Peña A, Zhang W, Brown T, Wise SD, Hall SD.

Drug Metab Dispos. 2012 Oct;40(10):1945-52. doi: 10.1124/dmd.112.046060. Epub 2012 Jul 12.

47.

Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Quinney SK, Malireddy SR, Vuppalanchi R, Hamman MA, Chalasani N, Gorski JC, Hall SD.

Eur J Clin Pharmacol. 2013 Mar;69(3):439-48. doi: 10.1007/s00228-012-1339-x. Epub 2012 Jul 10.

48.

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.

Thirumaran RK, Lamba JK, Kim RB, Urquhart BL, Gregor JC, Chande N, Fan Y, Qi A, Cheng C, Thummel KE, Hall SD, Schuetz EG.

Biochem Pharmacol. 2012 Jul 1;84(1):104-12. doi: 10.1016/j.bcp.2012.03.017. Epub 2012 Mar 30.

49.

QT effect of semagacestat at therapeutic and supratherapeutic doses.

Zhang W, Ayan-Oshodi M, Willis BA, Annes W, Hall SD, Chiesa J, Seger M.

Int J Clin Pharmacol Ther. 2012 Apr;50(4):290-9.

PMID:
22456300
50.

Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.

Mao J, Mohutsky MA, Harrelson JP, Wrighton SA, Hall SD.

Drug Metab Dispos. 2012 Apr;40(4):706-16. doi: 10.1124/dmd.111.043158. Epub 2012 Jan 6.

Supplemental Content

Support Center